Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and Drug Forecast to 2033

Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Report Overview

The Glucagon-like peptide-1 receptor (GLP-1R) agonists market across the 7MM was $31.3 billion in 2023. The market is expected to quadruple in the next 10 years, at a CAGR of more than 14%.

The GLP-1R agonists are a class of incretin mimetic medicines used to treat type 2 diabetes and obesity. They work by activating GLP-1 receptors, which are present in different regions of the body, such as on pancreatic beta-cells, in the GI tract, and hypothalamic and hindbrain regions of the brain. With the activation of the GPL-1 receptor, they exert their incretin-like activity, characterized by a potentiation of glucose-dependent insulin secretion, inhibition of glucagon secretion, decrease in food intake, and slowed gastric emptying. These effects directly improve insulin sensitivity and trigger satiety in type 2 diabetes and obesity patients.

GLP-1R Antagonist Market Outlook (2023-2033)

Buy the Full Report for More Insights into the GLP-1R Antagonist in the Type 2 Diabetes and Obesity Market, Download a Free Report Sample

GLP-1R Antagonist in Type 2 diabetes and obesity market research report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity market through 2033.

Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity – Key Drivers

• Increasingly high patient population
• An increase in drug-treatment rate is expected with the update of national guidelines.
• The entrance of new drugs with dual- and triple-agonist actions and combination therapies.

Buy the Full Report for More Driver Insights into the GLP-1R Antagonist in the Type 2 Diabetes and Obesity Market, Download a Free Report Sample

Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity – 7MM

Across the 7MM, there was considerable variation in the prevalence of T2D and obesity/overweight comorbidity. The US showed a higher proportion of cases expressing both obesity and T2D. This comorbidity was notably lower in Japan and Italy. Across all markets except Japan, the proportion of T2D cases with obesity or overweight exceeded cases of T2D without obesity.

GLP-1R Antagonist in Type 2 Diabetes and Obesity Market 7MM Analysis, 2023(%)

Buy the Full Report for More 7MM Insights into the GLP-1R Antagonist in the Type 2 Diabetes and Obesity Market, Download a Free Report Sample

Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity – Pipeline Assessment

The type 2 diabetes and obesity clinical pipelines include many GLP-1R agonists, some of which have dual- or triple-agonist properties. There are more than 50 pipeline GLP-1R agonist products in active development for type 2 diabetes and/or obesity in Phase I, II, and III stages of development. The pipeline also includes biosimilar products of liraglutide and exenatide, the two GLP-1R agonists on the market whose exclusivity is expired.

Scope

• Overview of GLP-1R agonists, type 2 diabetes, and obesity, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized GLP-1R agonists therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the GLP-1R agonists market.
• Pipeline analysis: comprehensive data assessing emerging trends and dual/triple mechanisms of action under development for type 2 diabetes and obesity medicines with a GLP-1R agonist action. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM GLP-1R agonists therapeutics type 2 diabetes and obesity market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model. Forecast includes US, 5EU, and Japan.

Forecast covers the period 2023-2033.

• 2023 base year sales within the GLP-1R agonists market are approximately $31.3billion across the 7MM detailed in this report. GlobalData estimates that the GLP-1R agonist market will grow at a compound annual growth rate (CAGR) of 14.9% to reach $125 billion by the end of the forecast period.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM GLP-1R agonists therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM GLP-1R agonists therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.